Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751559 | 0.80 | MC4R (0.44) | KDM1ADRD2POLBSIGMAR1ALDH1A1 | |
| SCHEMBL6746814 | 0.80 | — | — | |
| SCHEMBL6746847 | 0.80 | HTR2A (0.41) | — | |
| SCHEMBL6746868 | 0.79 | DRD2 (0.39) | HTR1ADRD2HTR6 | |
| SCHEMBL6748667 | 0.78 | HTR2A (0.31) | — | |
| SCHEMBL6746830 | 0.74 | ACHE (0.39) | SIGMAR1 | |
| SCHEMBL8342160 | 0.72 | ALDH1A1 (0.42) | HTR1ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL6748820 | 0.71 | DPP7 (0.36) | SIGMAR1SMN1; SMN2 | |
| SCHEMBL6751602 | 0.71 | CA12 (0.43) | MAPK1 | |
| SCHEMBL14281169 | 0.69 | HTR2A (0.43) | KDM1AHTR1ADRD2HTR6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703388-B2 | DIBENZODIAZEPINE DERIVATIVES; ANTIHISTAMINES, LEUKOTRIENE INHIBITORS, ANTIALLERGENS, ANTIASTHMATICS; HAY FEVER, ATOPIC DERMATITIS, AND URTICARIA TREATMENT | EISAI CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| US-6489336-B2 | PHENOTHIAZINE, ACRIDAN, ACRIDONE OXIME, ACRIDONE HYDRAZONE, OR DIBENZODIAZEPINE DERIVATIVES; TYROSINE KINASE INHIBITORS; TREATING ALLERGIC DISEASES | EISAI CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2002-08-01 | — | — | US | disclosed |
| US-6333322-B1 | FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, URTICARIA, HAY FEVER, GASTROINTESTINAL ALLERGY AND FOOD ALLERGY | EISAI CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0889037-A1 | NITROGENOUS TRICYCLIC COMPOUNDS AND DRUGS COMPRISING THE SAME | Eisai Co., Ltd. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | KDM1A 943/4885HTR1A 25/4885DRD2 238/4885 |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | KDM1A 943/4885HTR1A 25/4885DRD2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.